138 related articles for article (PubMed ID: 37258402)
1. Corrigendum to "Berberine regulates PADI4-related macrophage function to prevent lung cancer" [Int. Immunopharmacol. 110 (2022) 108965].
Gu W; Zhang M; Gao F; Niu Y; Sun L; Xia H; Li W; Zhang Y; Guo Z; Du G
Int Immunopharmacol; 2023 Jul; 120():110366. PubMed ID: 37258402
[No Abstract] [Full Text] [Related]
2. Berberine regulates PADI4-related macrophage function to prevent lung cancer.
Gu W; Zhang M; Gao F; Niu Y; Sun L; Xia H; Li W; Zhang Y; Guo Z; Du G
Int Immunopharmacol; 2022 Sep; 110():108965. PubMed ID: 35764017
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to 'In-vitro and in-vivo anti-breast cancer activity of synergistic effect of berberine and exercise through promoting the apoptosis and immunomodulatory effects' [Int. Immunopharmacol. 87 (2020) 106787].
Ma W; Zhang Y; Yu M; Wang B; Xu S; Zhang J; Li X; Ye X
Int Immunopharmacol; 2020 Nov; 88():106899. PubMed ID: 32827917
[No Abstract] [Full Text] [Related]
4. Corrigendum to "In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis" [Int. Immunopharmacol. 28(1) (2015) 34-43].
Zhou Y; Liu SQ; Peng H; Yu L; He B; Zhao Q
Int Immunopharmacol; 2022 Jul; 108():108844. PubMed ID: 35562271
[No Abstract] [Full Text] [Related]
5. Corrigendum to "In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis" [Int. Immunopharmacol. 28(1) (2015) 34-43].
Zhou Y; Liu SQ; Peng H; Yu L; He B; Zhao Q
Int Immunopharmacol; 2020 Sep; 86():106796. PubMed ID: 32674050
[No Abstract] [Full Text] [Related]
6. Corrigendum to "Anti-arthritis effect of berberine associated with regulating energy metabolism of macrophages through AMPK/HIF-1α pathway". [Int. Immunopharmacol. 87 (2020) 106830].
Yu Y; Cai W; Zhou J; Lu H; Wang Y; Song Y; He R; Pei F; Wang X; Zhang R; Liu H; Wei F
Int Immunopharmacol; 2021 Oct; 99():107911. PubMed ID: 34353734
[No Abstract] [Full Text] [Related]
7. Corrigendum to "Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells" [Int. Immunopharmacol. 125(Part A) (2023) 111139].
Feng Q; Hu K; Hu H; Lu Y; Zhang H; Wang G; Zhang Q; Xu Z; Gao X; Jia X; Zhu H; Song D; Yi H; Peng Y; Wu X; Li B; Zhu W; Shi J
Int Immunopharmacol; 2024 Jun; ():112499. PubMed ID: 38909009
[No Abstract] [Full Text] [Related]
8. Corrigendum to "GTS-21 attenuates ACE/ACE2 ratio and glycocalyx shedding in lipopolysaccharide-induced acute lung injury by targeting macrophage polarization derived ADAM-17" [Int. Immunopharmacol. 129 (2024) 111603].
Zhu W; Wang F; Hu C; Zhao Q; Zhang D; Wang X; Hu B; Li J
Int Immunopharmacol; 2024 May; 132():111914. PubMed ID: 38582738
[No Abstract] [Full Text] [Related]
9. Retraction notice to "Corrigendum to "MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region"" [Int. Immunopharmacol. 82 (2020) 106220] [Int. Immunopharmacol. 92 (2021) 107321].
Zhang Y; Ji T; Ma S; Wu W
Int Immunopharmacol; 2023 Apr; 117():109865. PubMed ID: 36822094
[No Abstract] [Full Text] [Related]
10. Corrigendum to "Hydrogen gas inhalation enhances alveolar macrophage phagocytosis in an ovalbumin-induced asthma model" [Int. Immunopharmacol. 74 (2019) 105646].
Huang P; Wei S; Huang W; Wu P; Chen S; Tao A; Wang H; Liang Z; Chen R; Yan J; Zhang Q
Int Immunopharmacol; 2022 Nov; 112():109124. PubMed ID: 36070977
[No Abstract] [Full Text] [Related]
11. Corrigendum to "Evaluation of the immunomodulatory and anti-inflammatory activity of Bakuchiol using RAW 264.7 macrophage cell lines and in animal models stimulated by lipopolysaccharide (LPS)" [Int. Immunopharmacol. 91 (2021) 107264].
Kumar A; Sawhney G; Kumar Nagar R; Chauhan N; Gupta N; Kaul A; Ahmed Z; Sangwan PL; Satheesh Kumar P; Yadav G
Int Immunopharmacol; 2022 Oct; 111():109003. PubMed ID: 35778365
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Rapamycin regulates osteogenic differentiation through Parkin-mediated mitophagy in rheumatoid arthritis" [Int. Immunopharmacol. 113(Part B) (2022) 109407].
Chen Q; Fan K; Song G; Wang X; Zhang J; Chen H; Qin X; Lu Y; Qi W
Int Immunopharmacol; 2023 Nov; 124(Pt A):110941. PubMed ID: 37718175
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Oridonin regulates the polarized state of Kupffer cells to alleviate nonalcoholic fatty liver disease through ROS-NF-κB" [Int. Immunopharmacol. 101(Part B) (2021) 108290].
Zhu Y; Ruan S; Shen H; Guan Q; Zhai L; Yang Y
Int Immunopharmacol; 2023 Jun; 119():110302. PubMed ID: 37193623
[No Abstract] [Full Text] [Related]
14. Corrigendum to "Plasma levels of 12 different cytokines correlate to PD-1 inhibitor combined chemotherapy responses in advanced non-small-cell lung cancer patient" [Int. Immunopharmacol. 124(Part A) (2023) 110888].
Peng Y; Qi Q; Zhu M; Zhang Y; Bao Y; Liu Y
Int Immunopharmacol; 2023 Nov; 124(Pt A):110976. PubMed ID: 37778965
[No Abstract] [Full Text] [Related]
15. Corrigendum to "Emodin attenuates acute lung injury in cecal-ligation and puncture rats" [Int. Immunopharmacol. 85 (2020) 106626].
Guo R; Li Y; Han M; Liu J; Sun Y
Int Immunopharmacol; 2023 Sep; 122():110700. PubMed ID: 37507324
[No Abstract] [Full Text] [Related]
16. Corrigendum to "Inhibition of MRP4 alleviates sepsis-induced acute lung injury in rats" [Int. Immunopharmacol. 72 (2019) 211-217].
Xia W; Zhang H; Pan Z; Li G; Zhou Q; Hu D; Liu Y
Int Immunopharmacol; 2023 Sep; 122():110699. PubMed ID: 37500384
[No Abstract] [Full Text] [Related]
17. Corrigendum to "MEGF6 prevents sepsis-induced acute lung injury in mice" [Int. Immunopharmacol. 123 (2023) 110727].
Liang H; Liu G; Zeng W; Fan Q; Nie Z; Hu H; Zhang R; Xie S
Int Immunopharmacol; 2024 May; 133():111787. PubMed ID: 38641473
[No Abstract] [Full Text] [Related]
18. Corrigendum to "Sophoricoside attenuates lipopolysaccharide-induced acute lung injury by activating the AMPK/Nrf2 signaling axis" [Int. Immunopharmacol. 90 (2021) 107187].
Wu YX; Zeng S; Wan BB; Wang YY; Sun HX; Liu G; Gao ZQ; Chen D; Chen YQ; Lu MD; Pang QF
Int Immunopharmacol; 2023 Nov; 124(Pt A):111008. PubMed ID: 37806791
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway" [Int. Immunopharmacol. 96 (2021) 107566].
Islam J; Shree A; Vafa A; Afzal SM; Sultana S
Int Immunopharmacol; 2023 Jun; 119():110096. PubMed ID: 37095029
[No Abstract] [Full Text] [Related]
20. Corrigendum to "Salidroside postconditioning attenuates ferroptosis-mediated lung ischemia-reperfusion injury by activating the Nrf2/SLC7A11 signaling axis" [Int. Immunopharmacol. 115 (2023) 109731].
Wang Y; Chen Z; Luo J; Zhang J; Sang AM; Cheng ZS; Li XY
Int Immunopharmacol; 2023 Apr; 117():110002. PubMed ID: 36925352
[No Abstract] [Full Text] [Related]
[Next] [New Search]
